(Press-News.org) LA JOLLA, CA – January 31, 2011 –A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.
The findings, from a study by Scripps Research Assistant Professor Laurent O. Mosnier, were published in a recent edition of Journal of Biological Chemistry.
The study focused on Platelet Factor 4 – a small cytokine (intracellular signaling molecule) released during platelet aggregation.
Based on Platelet Factor 4 effects on another coagulation protein, it was thought that Platelet Factor 4 could potentially stimulate activation of thrombin-activatable fibrinolysis inhibitor (TAFI) – an enzyme (soluble protein) that protects clot longevity, making clots last longer and preventing excess bleeding; TAFI is like a hardener that is added to the mortar used between the bricks in a brick wall, without which the mortar would never completely solidify, and the wall would never be solid.
The new study, however, found exactly the opposite role for Platelet Factor 4—inhibition of TAFI activation.
For Mosnier, this finding led to a radical idea—sequestering Platelet Factor 4 using such molecules as heparin derivatives could improve clot stability. Heparin - a highly sulfated or negatively charged glucoseaminoglycan (polysaccharide or sugar derivative) – is a commonly used anticoagulant. Mosnier, however, was able to modify the compound to have the reverse effect and aid in blood clotting in laboratory tests.
"The idea of using heparin to prevent bleeding in kids [who have bleeding tendencies] would be outrageous because that would just greatly accelerate bleeding," said Mosnier, "Our trick, however, was to modulate heparin's anticoagulant properties. This opens up new possibilities."
Converting Heparin from an Anticoagulant into a Non-Anticoagulant
Heparin's anticoagulant activity is derived from a specific pattern of nitrogen- and oxygen-linked sulfation (or simply negative charges) that is recognized by anti-thrombin – the inactivator of coagulation. However, in addition to binding to anti-thrombin heparin also binds to Platelet Factor 4, which is glittered with positive charge, and they attract one another like magnets.
Mosnier found heparin's anticoagulant activity could be prevented, and its Platelet Factor 4 binding selected for, by selectively removing the N-linked sulfations (and further acetylation). This effectively prevented heparin from being recognized by anti-thrombin and allowed it to instead take the Platelet Factor 4 out of the equation. This resulted in prevention of clot breakdown (fibrinolysis), by allowing TAFI to do its job.
To test the effectiveness of the modified heparin derivatives in enhancing clot stability, Mosnier employed a functional assay called a "clot lysis assay." Using a light scattering technique, plasma was used to generate a clot, which was degraded. Further modulation of the conditions allowed measurement of clot stability via TAFI activation. Mosnier found that, indeed, the modified-version heparin promoted clot stability.
Toward a Cheaper, Cost-Effective Treatment for Hemophilia A
An optimistic Mosnier admits his new discovery is in its infancy, but hopes it may one day provide an alternative treatment for bleeding conditions such as Hemophilia A.
Hemophilia A, which affects 1 in 5,000 males, is an X-linked genetic bleeding disorder whereby there is a reduced amount or activity of factor VIII. This results in the unstable clots, lacking fibrin – a fibrous clot-forming protein. Currently, the treatment for Hemophilia A is prophylactically taking factor VIII as a medicine to improve clotting. Unfortunately, immunity against factor VIII is a significant side effect.
Mosnier hopes that modification of heparin – which is cheaper than factor VIII and already used clinically – could one day stabilize clots in these patients.
"The next step is to see if the modified compound will improve bleeding complications in the Hemophilia mouse," said Mosnier. "We are still a long way from claiming anything clinically."
His optimism is contagious, however, and it is an exciting time for science in the Mosnier lab.
INFORMATION:
Professor Laurent O. Mosnier of the Scripps Research Institute was sole author of the study, "Platelet Factor 4 Inhibits Thrombomodulin-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) by Thrombin." For more information, see http://www.jbc.org/content/286/1/502.full?sid=7795e622-9966-4a9a-b999-0eb4d69e474a.
This research was funded by a "Pathway to Independence Grant," which enabled the establishment of the Mosnier Lab, from the National Institute of Health (NHLBI Grant HL087618).
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, Scripps Research currently employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Headquartered in La Jolla, California, the institute also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Florida. For more information, see www.scripps.edu.
END
January 31, 2011 (Portland, Ore.) – Obese women may avoid mammograms because of pain and women under 60 may avoid the test because they are too busy, according to a study by Kaiser Permanente Center for Health Research published online in the Journal of Women's Health. Funded by the National Cancer Institute, the study was one of the largest to examine why insured women fail to complete mammograms.
Breast cancer is the most common cancer among women in the United States, with one in eight developing breast cancer during their lifetimes, and 46,000 dying from it annually. ...
Researchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread.
By measuring the protein's genetic material in tumors that had been surgically removed from patients, along with measuring the genetic material from surrounding tissue, the researchers could predict at least 90 percent of the time whether a cancer would spread within two years.
The findings raise the long term possibilities of new tests to gauge the likelihood that ...
Two separate studies – carried out in Burkina Faso and Mali– have found that combining intermittent preventive treatment of malaria in children (IPTc) with insecticide-treated bednets (ITNs) can substantially reduce the incidence of severe malaria.
A third study carried out in The Gambia supported the findings, reporting that IPTc treatment was not only easily administered by village health workers, but could also significantly reduce the incidence of malaria among children.
All three studies, published today in the journal PLoS Medicine, will further strengthen the ...
Three randomized controlled trials published in this week's PLoS Medicine show that intermittent preventive treatment of malaria in children adds to the benefit of sleeping under bednets and that this public health intervention is best delivered by community-based, volunteer village health workers.
Two randomized controlled trials (with over 3000 children in each study) carried out by a team of researchers led by Diadier Diallo from the London School of Hygiene & Tropical Medicine, London, UK, Amadou Konate from the Centre National de Recherche et de Formation sur le ...
When you think about organs with an important role in reproduction, the liver most likely doesn't spring to mind. But a new report in the February issue of Cell Metabolism, a Cell Press publication, shows that estrogen receptors in the liver are critical for maintaining fertility. What's more, the expression of those receptors is under the control of dietary amino acids, the building blocks of proteins.
The findings in mice may have important implications for some forms of infertility and for metabolic changes that come with menopause, the researchers say.
"This is ...
After taking a small dose of inorganic nitrate for three days, healthy people consume less oxygen while riding an exercise bike. A new study in the February issue of Cell Metabolism traces that improved performance to increased efficiency of the mitochondria that power our cells.
The researchers aren't recommending anyone begin taking inorganic nitrate supplements based on the new findings. Rather, they say that the results may offer one explanation for the well-known health benefits of fruits and vegetables, and leafy green vegetables in particular.
"We're talking ...
Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease — tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit. In this context, a team of researchers — led by Peng Loh, at the National Institutes of Health, Bethesda; and Ronnie Poon, at the The University of Hong Kong, China — has now identified a potential biomarker for predicting future metastasis in patients with the most ...
EDITOR'S PICK: Predicting liver cancer spread
Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease — tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit. In this context, a team of researchers — led by Peng Loh, at the National Institutes of Health, Bethesda; and Ronnie Poon, at the The University of Hong Kong, China — has now identified a potential biomarker for predicting ...
STANFORD, Calif. — Many patients with rheumatoid arthritis, a crippling disease that causes pain, swelling and eats away at the joints, aren't receiving the much-needed, low-cost medications that can prevent deformity.
Despite medical guidelines recommending that patients receive early and aggressive treatment for rheumatoid arthritis with these medications, only 63 percent of Medicare-managed care patients diagnosed with the disease received any amount of the prescription drugs, according to a new study led by a researcher from the Stanford University School of Medicine ...
A parent's wise advice to never go to a hospital unless you want to get sick may be gaining support from scientific studies on a specific airborne virus.
The results of a Virginia Tech study by environmental engineers and a virologist on the risk of airborne infection in public places from concentrations of influenza A viruses is appearing today in the on-line, Feb. 2 issue of the United Kingdom's Journal of the Royal Society Interface.
Linsey Marr, associate professor of civil and environmental engineering at Virginia Tech, http://www.cee.vt.edu/people/lmarr.html and ...
